Samantha Bobba, Nick Di Girolamo, Megan Munsie, Stephanie Watson
Purpose: To review approaches to ocular stem cell therapy based on current progress in clinical trials and professional practice standards.
Method: A systemic literature review was con- ducted (Ovid MEDLINE, PubMed and EMBASE databases searched, January 1989 ? June 2017) and clinical trial registries reviewed (ClinicalTrials.gov, The World Health Organisation International Clini- cal Trials Registry Platform and Cochrane Central Register of Controlled Trials). Guidelines and codes of conduct from organisations including the Thera- peutic Goods Administration, Royal Australian and New Zealand College of Ophthalmologists and Australian Medical Association were reviewed. Data was extracted and collated on progress in corneal and retinal stem cell therapy, the clinical trial pro- cess and ethical considerations.
Results: Forty-one clinical trials of ocular surface stem cell transplantation used to treat limbal stem cell deftciency were identifted. Only fourteen stud- ies had greater than two years follow-up, with an average success rate of 72%. Whilst clinical trial reg- istries listed additional studies, only four Phase I/II clinical trials had been published on retinal cell transplantation with a mean success rate of 77% in 22 patients. These studies utilised induced or plu- ripotent human embryonic stem cell sources. Alter- native approaches utilising trabecular, neural, ciliary body and iris pigment stem cells require further ani- mal/in vivo studies prior to human trials.
Conclusion: Ocular stem cell therapy is experimen- tal and should operate within formal clinical trial frameworks. This is the ftrst review to encompass both corneal and retinal cell transplantation, provid- ing a comprehensive overview that could provide the basis for a Position Statement on ocular stem cell therapy.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY